Prognosis of PH is poor and both diagnosing and treating patients is challenging. The gold standard for diagnosing PH is right-sided heart catheterization, however this is an invasive procedure. Reliable, validated biomarkers would have the advantage as they can be assessed using samples acquired from a simple blood draw.
Biomarkers that specifically indicate the disease, the disease stage and the treatment response to specific therapies would be an ideal set of tools used while optimizing the management of PH patients. In addition, monitoring PH via biomarkers would be important to better define the urgency for lung transplantation in patients with a disease that is refractory to any treatment.